Background: Despite the considerable progress that has been achieved in the
Introduction
Susceptibility to infections in early life can be attributed to inadequate immune protection against the multiple infections to which infants and young children are constantly exposed 1 . For most infections, antibodies correlate strongly with protective immunity as demonstrated by the fact that most licenced vaccines function through the induction of functional antibodies 2 . In early life, these protective antibodies can be also derived from alternative sources including the immune response mounted against infection, passively-acquired maternal antibody 3 and maternal breast milk 4 . Antibodies from different sources contribute towards an immune repertoire whose breadth defines the range of infections to which an individual is susceptible. In order to comprehensively profile the antibody repertoire against infectious diseases in early life, it is necessary to simultaneously measure antibodies against multiple antigens within a single biological sample. Traditional detection techniques such as the ELISA are generally limited to a single antigen and are therefore constrained to addressing only a small set of research hypotheses. In addition, most antibody detection assays are based on serum which is only one of a range of tissues in which these molecules mediate their effector functions.
Except for blood-borne pathogens, antibodies exert most of their functional roles in tissue, including the mucosal surfaces of the respiratory, gastrointestinal and urinary tracts 5, 6 . Protein microarray-based immunoassays are emerging technologies that permit the multiplexed detection of antibodies against a variety of antigens 7 . These technologies combine the capacity for highly parallel miniaturisation that is inherent to microarrays to the highly specific interactions between antigens and antibodies to construct a detection system that is capable of quantifying antibodies against hundreds of antigens within a single assay 8 . Peptide microarray-based immunoassays on the other hand have been used less extensively in clinical research and unlike protein microarray-based immunoassays, they utilise single linear epitopes from immuno-dominant regions of a protein as antigens [9] [10] [11] . Apart from mimicking well-defined epitopes that are highly specific to a particular pathogen 9, 12, 13 , this approach provides additional advantages over proteinbased arrays, including reduced antigen cost, relative technical simplicity of peptide synthesis and the enhanced shelf-life of peptide array chips. Using a library of previously validated linear epitopes, we developed a synthetic peptide-based microarray for the detection of antibodies against multiple infectious diseases in a single microarray chip.
We optimised the workflow to allow for the simultaneous quantification of two antibody subclasses in both serum and secretions derived from the airway mucosa of infants and young children. Using the data generated from the chip, we examined the systemic and secretory antibody repertoire against forty one infectious diseases in the first year of life.
We also used the data to determine the kinetics of maternal antibody decay during this period.
Materials and Methods

Study site and population
The study was conducted in Kilifi County, a rural community on the Kenyan coast. 38 children (age range: 25 days -17.5months) attending two local healthcare facilities (Kilifi County Hospital and the Pingilikani dispensary) with different infections were recruited into the study. Serum and nasopharyngeal and oropharyngeal swabs were collected from each child using previously described methods 14 . Written informed consent was obtained from the parents and legal guardians of all participants prior to recruitment. Ethical clearance for the conduct of the study was provided by the Kenya Medical Research Institute's Scientific, Ethical and Research Unit.
Selection of linear epitopes for the development of a peptide microarray immunoassay
We used the Immune Epitope Database 15 (IEDB) to construct a library of forty one experimentally-validated linear epitopes from a selection of infectious disease pathogens with moderate to high prevalence within the local population. Epitope sequences were sourced from previously published literature, where they had been independently validated using specific disease cohorts of naturally or experimentally-infected subjects.
Two distinct epitopes were selected for each pathogen, with the epitope pairs in many cases being derived from different proteins. Details of the epitopes that were selected including source protein, amino acid sequence and source publication are outlined in table S1. The 82 linear epitopes (two for each of the 41 pathogens) were expressed as synthetic peptides by a commercial service provider (GenScript) with a free amino acid conjugated to each peptide.
Development of peptide microarray chip
Lyophilised peptides were dissolved in a printing buffer consisting of 70% dimethyl sulfoxide, 5% glycerol and 25% sodium acetate (pH adjusted to 4.5). 50µl of the peptide solution was loaded onto the wells of a 384-well plate prior to printing. Peptides that did not fully dissolve were sonicated for 5 minutes and a further attempt to re-dissolve them was made. Functionalized 2D-epoxy glass slides (PolyAn, Germany) onto which the peptides were to be printed, were first dried on a heating block at 100 o C for 10 minutes to remove residual moisture. Peptides were printed onto the epoxy slides using a noncontact inkjet microarray printer (Arrayjet, Scotland). Two peptide droplets of 100 picolitres each were printed onto the dried functionalized epoxy glass slides at a temperature of 20 o C and 50% humidity. In addition to the peptides, the following control antigens were directly printed onto the slides: (i) an unlabelled capture antibody specific to the human IgG heavy chain and (ii) antibodies conjugated to fluorescent reporter labels (Alexa-Fluor 647 and Alexa Fluor 555: these antibodies were directly printed onto the slides in a pre-specified pattern as orientation landmarks). The capture antibody bound to all IgG molecules in the sample regardless of antigen specificity and provided process quality information on the printing and signal acquisition processes. In addition, negative control spots consisting of printing buffer were printed on each mini-array in order to identify non-specific antibody binding within individual mini-arrays. Printed slides were initially left to dry for one hour within the printing chamber and then at 25 o C for 2 days in a dehumidified chamber. After drying, slides were then loaded onto 24-chamber hybridization cassettes and firmly locked into position. The slides were initially washed two times with PBS containing Tween-20 and then twice with only PBS. Blocking was done for one hour using 5% BSA in SSC buffer (0.25% SDS and 4.5% NaCl, adjusted to pH 7.0).
In order to detect mucosal antibodies in airway samples, transport media (UTM, Copan diagnostics) into which nasopharyngeal and oropharyngeal swabs (Copan diagnostics) had been eluted, were spun at 14000 rpm for 5 minutes in order to pellet cells and 
Data analysis
Data were analysed in the R programming environment 16 . Since each peptide was printed in duplicate, mean MFI values were calculated for each duplicate pair prior to analysis. For each pathogen, two distinct peptides were synthesised and printed onto the chip.
Peptide-specific MFIs were compared between peptide pairs from the same pathogen and the peptide that exhibited the higher MFI signal was selected for further analysis. Loess curve-fitting was used to visualise the age-related antibody kinetics of a selection of antigens on the peptide microarray chip. 
Discussion
We report the development of a synthetic peptide-based microarray for the measurement of antibody levels against forty-one infectious disease pathogens in serum and airway mucosal samples. The data from the microarray were used to explore the systemic and mucosal antibody repertoire against different infectious disease antigens in the first 18 months of life. Our data showed that during this period, most children had high levels of antibody against antigens derived from five infections: Epstein-Barr virus (EBV), poliovirus, Streptococcus pneumoniae, plasmodium falciparum and varicella zoster in both serum and the airway mucosa. In the first few months of life, it can be assumed that most of these antibodies are maternally-derived. The maternal antibody repertoire -delivered to the infant via breast milk or by trans-placental transfer -reflects lifelong maternal exposure to infectious disease and presents a snapshot of the locally prevalent infectious diseases 17 . In this study, some of the infections that were most frequently recognised within the study population have been previously documented to cause a very high disease burden within the east African coastal region in which the study recruits reside. For example, plasmodium falciparum, which causes malaria, has traditionally been endemic on the Kenyan coast and has been associated with a considerable annual morbidity and mortality burden over many decades [18] [19] [20] . In areas of comparable endemicity, approximately 40% of children under the age of five years have been reported to have circulating antibody against the parasite 21 , suggesting that women of child bearing age have high levels of circulating IgG available for transplacental transfer to foetal circulation. In the case of EBV, there is strong evidence from different parts of the world that infection is generally acquired within the first few years of life and that up to one in three children are EBV-seropositive by the age of five years [22] [23] [24] [25] . This early exposure profile suggests that the widespread recognition of EBV antigens in this study could be traced to a combination factors including responses to natural infection as well as passively acquired maternal antibody as a result of long-term maternal exposure. In addition to EBV, we also observed an abundance of serum and mucosal antibody against the Streptococcus pneumoniae, a common mucosal pathobiont that normally colonises the upper respiratory tract in early life 26 and is also the cause of pneumococcal pneumonia. Previous studies in Kilifi have shown that pneumonia is the biggest cause of childhood admissions 27 and that pneumococcal pneumonia is responsible for about half of those admissions 28 . In addition to these pathogens, we also observed high antibody levels against poliovirus across the study population. We speculate that in addition to transplacental transfer, the poliovirus specific antibodies that were identified in the study population were as a result of vaccination. In Kenya, the oral polio vaccine (OPV) is administered to all infants at birth, 10 weeks and 14 weeks of age. This means that at the time of presentation to hospital, children in this study would have received at least one OPV dose and for a few of the children, all three doses. Taken together, the data presented are largely consistent with ancillary data on natural exposure, vaccination and maternal antibody transfer and suggests that the platform can be reliably used for more extensive serological analysis in future studies. In this study, we only included a limited number of antigens to provide initial proof-of-concept data. Due to its capacity for additional scalability, this platform can be expanded to incorporate and even broader array of infectious disease targets -including emerging threats such as ZIKA, Ebola and MERS -allowing a for more comprehensive profiling of humoral immunity in children.
We found evidence that antibodies against some antigens were differentially distributed between the serum and the airway mucosa. For example antibodies against echinococcus granulosus were detected more frequently in mucosal samples compared to serum. This difference might be attributed to the fact that echinococcus granulosus is a mucosal pathogen, and the host immune response against it is likely to be co-ordinated by immune cells resident in mucosal tissue. Animal studies have shown that experimental infection results in the production of high levels of anti echinococcus granulosus antibodies that can be detected in mucosal samples -including saliva -but not in serum 29 . Contrary to our expectations, some antigens that were derived from highly prevalent infections were detected at very low frequencies within the study population. For example, antibodies against influenza A (FLUA), a highly transmissible respiratory virus, were only detected sporadically. One possible explanation for this unexpected observation is antigenic mismatching between the assay antigen and that of locally circulating influenza A strains.
The influenza A epitopes in this work were derived from the hemagglutinin (HA) protein, a highly variable protein that is characterised by temporal antigenic drifts in response to a build-up of population immunity 30 . Although we did not genetically characterise locally circulating influenza A strains over the course of the study, it unlikely that the HA sequences of these viruses would be identical to the HA antigen used on the microarray chip 31 that circulated in the United States almost ten years earlier. Using data from the microarray, we also examined the age-related dynamics of antibodies specific to the five most frequently detected infections: EBV, poliovirus, S. pneumoniae, v. zoster and P.
falciparum. With the exception of the pneumococcus, IgG levels in serum and the airway mucosa declined rapidly in the first three months of life, indicating the passive decay of maternally derived antibodies as has been extensively documented for numerous other infections 3, 32, 33 . In the case of the pneumococcus, we observed a general increase in the level of serum IgG throughout the first year of life. Previous studies have demonstrated that colonisation of the upper airway by the pneumococcus, tends to occur at a very early age. Studies in African infants have shown that over a third of all neonates are colonised with the pneumococcus within the first 28 days of life 34 . This early exposure profile might explain our failure to observe a decline in maternal pneumococcal IgG, since this decline would have been offset by the concurrent acquisition of natural antibody against colonising pneumococci. In sum, the observed kinetics of maternal antibodies in the first few months of life are consistent with expectations and largely align with previous observations. Apart from profiling antibody immunity in early life, the peptide microarray chip we've developed can be also be leveraged for different clinical and research applications including seroepidemiological studies. Previous studies have assayed antibodies to numerous infections as a proxy marker of disease exposure, and the resulting serology data have used to estimate disease burden [35] [36] [37] [38] [39] . The productive output of such seroepidemiological surveys can vastly be increased if in addition to the target antigen other related antigens are concurrently assayed, thereby providing a broader picture of disease interactions. 1 1 1 1 1 1 1 1 2 2 2 2 2 3 3 3 3 SFLX  STAU  LDON  MYBT  ADV2  STYP  HSV1  HV6B  MYBB  ONCV  KPNE  HPYL  HPVI  HINF  ROTV  ENTH  SMAN  RUBV  CTET  HEPB  BORP  WUCB  BRUM  SARS  TRBG  DEN2  HV12  HRVB  TRCR  MENB  HEPC  TSOL  ECHG  HEPA  VZOS  POLV  PFAL  EBVI ENTH  HRVB  KPNE  MYBB  ROTV  STYP  CTET  HPYL  LDON  MYBT  ONCV  STAU  DEN2  FLUA  HINF  HPVI  HSV1  HV12  PSAR  SFLX  MENB  RUBV  WUCB  HEPB  HEPC  SMAN  HV6B  TRBG  SARS  TRCR  HEPA  TSOL  BORP  ECHG  POLV  PFAL  VZOS  EBVI KPNE  HRVB  ONCV  ROTV  MYBB  HSV1  PSAR  BRUM  MYBT  HV6B  ENTH  STAU  SFLX  CTET  STYP  HINF  FLUA  DEN2  HPVI  ADV2  ECHG  SARS  HPYL  HEPC  MENB  WUCB  TRBG  SMAN  BORP  TRCR  RUBV  TSOL  HEPA  HEPB  HV12  VZOS  PFAL  SPNE  POLV ENTH  FLUA  HEPB  HINF  HPYL  HSV1  HV6B  KPNE  LDON  MYBB  MYBT  ONCV  ROTV  RUBV  SFLX  STAU  STYP  WUCB  PSAR  HPVI  SMAN  TRBG  SARS  CTET  BRUM  HEPC  BORP  HV12  TRCR  TSOL  HEPA  HRVB  DEN2  ECHG  VZOS  MENB  POLV  EBVI  PFAL  SPNE Proportion with detectable (MFI>0) antibody level (%) 
